{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:21:32Z","timestamp":1790806892500,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neovascular age-related macular degeneration (nAMD) is a major cause of vision loss in older adults. While anti-VEGF therapies have improved management by suppressing abnormal blood vessel growth, a substantial subset of patients show poor functional as well as morphological responses and require frequent injections. Faricimab (Vabysmo\u00ae), a bispecific inhibitor targeting VEGF-A and angiopoietin-2 (Ang-2), has shown promise in achieving more durable disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 48 eyes from 47 nAMD patients previously treated with ranibizumab or aflibercept, who were switched to faricimab due to poor treatment response. Evaluations occurred at four time points, assessing best-corrected visual acuity (BCVA), intraretinal (IRF) and subretinal fluid (SRF), subretinal pigment epithelium fluid and fibrosis, central subfield thickness (CST), and central subfield volume (CSV) using spectral-domain OCT. Dosing intervals and patient-reported outcomes were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BCVA improved consistently, with mean logMAR improving from 0.54 to 0.40, reflecting a gain of 1.4 Snellen lines. Dosing intervals extended from a median of 5 to 8\u00a0weeks, with over one-third of eyes reaching intervals of 10\u00a0weeks or more. Significant reductions in IRF, SRF, CST as well as CSV were observed (p\u2009&lt;\u20090.05) with a quarter of eyes showing no intra- or subretinal fluid at the fourth faricimab injection. Three patients were switched back to their previous anti-VEGF treatment due to a decline in BCVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The findings suggest Faricimab as an effective option for nAMD patients who respond inadequately to prior anti-VEGF therapies, offering both functional and anatomical improvements. Extended intervals reduce treatment burden, indicating faricimab\u2019s potential to enhance disease control and patient quality of life in real-world settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03525-2","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:09:22Z","timestamp":1746691762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0848-0630","authenticated-orcid":false,"given":"Nathalie","family":"Bleidi\u00dfel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weichenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Spielberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"11","key":"3525_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","volume":"34","author":"AP Adamis","year":"2020","unstructured":"Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ (2020) Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond) 34(11):1966\u20131972","journal-title":"Eye (Lond)"},{"issue":"11","key":"3525_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/biom12111629","volume":"12","author":"RH ElSheikh","year":"2022","unstructured":"ElSheikh RH, Chauhan MZ, Sallam AB (2022) Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules 12(11):1629. https:\/\/doi.org\/10.3390\/biom12111629","journal-title":"Biomolecules"},{"issue":"6","key":"3525_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 29(6):721\u2013731","journal-title":"Eye (Lond)"},{"issue":"8","key":"3525_CR4","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire, M. G., Martin, D. F., Ying, G. S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., 3rd, & Fine, S. L","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire, M. G., Martin, D. F., Ying, G. S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., 3rd, & Fine, S. L (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123(8):1751\u20131761","journal-title":"Ophthalmology"},{"key":"3525_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/OPTH.S231913","volume":"16","author":"CS Tan","year":"2022","unstructured":"Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR (2022) Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol (Auckland NZ) 16:917\u2013933","journal-title":"Clin Ophthalmol (Auckland NZ)"},{"issue":"7","key":"3525_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M (2022) Faricimab: first approval. Drugs 82(7):825\u2013830","journal-title":"Drugs"},{"issue":"4","key":"3525_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C (2021) TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci 1(4):100076","journal-title":"Ophthalmol Sci"},{"issue":"10326","key":"3525_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY, TENAYA and LUCERNE Investigators, (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet (London, England) 399(10326):729\u2013740","journal-title":"Lancet (London, England)"},{"key":"3525_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03364-y","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, Xue K, Cehajic-Kapetanovic J, MacLaren RE, Charbel Issa P, Downes SM, De Silva SR (2024) Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). https:\/\/doi.org\/10.1038\/s41433-024-03364-y","journal-title":"Eye (Lond)"},{"issue":"11","key":"3525_CR10","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G (2024) One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Therapy 13(11):2985\u20132997","journal-title":"Ophthalmol Therapy"},{"issue":"16","key":"3525_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S (2024) Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond) 38(16):3059\u20133064","journal-title":"Eye (Lond)"},{"issue":"1","key":"3525_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA, for Japan AMD Research Consortium (JARC) (2024) Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefe\u2019s Archive Clin Exp Ophthalmol 262(1):43\u201351","journal-title":"Graefe's Archive Clin Exp Ophthalmol"},{"issue":"4","key":"3525_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2024.100074","volume":"1","author":"C Weber","year":"2024","unstructured":"Weber C, Schipper P, Stasik I, Weinhold L, Bulirsch L, Thiele S, Holz F, Liegl R (2024) Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study. AJO Int 1(4):100074","journal-title":"AJO Int"},{"key":"3525_CR14","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB (2023) One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ) 17:2201\u20132208","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"15","key":"3525_CR15","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM (2023) Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond) 37(15):3282\u20133289","journal-title":"Eye (Lond)"},{"issue":"2","key":"3525_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, Paladini L, Barratt J, Wong TY, Loewenstein A (2021) Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 128(2):234\u2013247","journal-title":"Ophthalmology"},{"issue":"1","key":"3525_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1159\/000527815","volume":"66","author":"PK Kaiser","year":"2023","unstructured":"Kaiser PK, Giani A, Fuchs H, Chong V, Heier JS (2023) Factors that can prolong ocular treatment duration in age-related macular degeneration. Ophthalmic Res 66(1):653\u2013663","journal-title":"Ophthalmic Res"},{"issue":"4","key":"3525_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/pharmaceutics16040470","volume":"16","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD (2024) First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics 16(4):470","journal-title":"Pharmaceutics"},{"issue":"7","key":"3525_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J (2024) Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefe\u2019s Arch Clin Exp Ophthalmol 262(7):2153\u20132162","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3525_CR20","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A (2023) Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep 13(1):21128","journal-title":"Sci Rep"},{"issue":"2","key":"3525_CR21","first-page":"193","volume":"14","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, Mushtaq B, Chavan R, Chong YJ (2024) Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel, Switzerland) 14(2):193","journal-title":"Life (Basel, Switzerland)"},{"issue":"6","key":"3525_CR22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, Steel DH, Grinton M (2024) Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina 8(6):537\u2013544","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"3525_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.65.11.15","volume":"65","author":"T Todoroki","year":"2024","unstructured":"Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, Kaneko H, Nishiguchi KM (2024) Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab. Invest Ophthalmol Vis Sci 65(11):15","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3525_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","volume":"142","author":"L Thangamathesvaran","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, Ar\u00e9valo JF, Bressler NM (2024) Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol 142(4):365\u2013370","journal-title":"JAMA Ophthalmol"},{"key":"3525_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004394","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, Nicholson L, Papasavvas I, Tucker WR, Yeung I (2025) Intraocular inflammation (ioi) associated with faricimab therapy: one-year real world outcomes. Retina (Philadelphia, Pa). https:\/\/doi.org\/10.1097\/IAE.0000000000004394","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"12","key":"3525_CR26","volume":"16","author":"S Parakh","year":"2024","unstructured":"Parakh S, Bhatt V, Das S, Lakhlan P, Luthra G, Luthra S (2024) Intraocular inflammation following intravitreal faricimab injection in neovascular age-related macular degeneration. Cureus 16(12):e75937","journal-title":"Cureus"},{"key":"3525_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","volume":"269","author":"I Ben Ghezala","year":"2025","unstructured":"Ben Ghezala I, Gabrielle PH, Sibert M, Steinberg LA, Dautriche A, Arnould L, Creuzot-Garcher C (2025) Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients. Am J Ophthalmol 269:11\u201319","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"3525_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","volume":"142","author":"M Cozzi","year":"2024","unstructured":"Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA (2024) Sterile intraocular inflammation associated with faricimab. JAMA Ophthalmol 142(11):1028\u20131036","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"3525_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40942-025-00629-w","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, Forte P, Forte G, Eandi CM (2025) Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Na\u00efve and switch eyes. Int J Retina Vitreous 11(1):3","journal-title":"Int J Retina Vitreous"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03525-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:30Z","timestamp":1766167470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03525-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3525"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03525-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. Approval was obtained from the ethics committee of Technical University of Munich. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This type of study does not require informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"MM and NF has received honoraria for lectures from Roche, Bayer, AbbVie and Novartis, and travel support from Roche and Bayer. NB has received honoraria for lectures from Roche, Bayer and Novartis, and travel support from Roche and Bayer. The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"177"}}